Mark Hopman Sells 856 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 856 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $29.34, for a total value of $25,115.04. Following the completion of the sale, the insider directly owned 138,277 shares of the company’s stock, valued at $4,057,047.18. The trade was a 0.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mark Hopman also recently made the following trade(s):

• On Wednesday, March 4th, Mark Hopman sold 353 shares of Beta Bionics stock. The stock was sold at an average price of $11.57, for a total value of $4,084.21.
• On Monday, March 2nd, Mark Hopman sold 834 shares of Beta Bionics stock. The shares were sold at an average price of $12.36, for a total value of $10,308.24.

Beta Bionics Stock Performance

Beta Bionics stock opened at $10.64 on Wednesday. The stock has a market cap of $472.20 million, a PE ratio of -5.46 and a beta of 5.60. The stock has a 50-day moving average of $14.73 and a two-hundred day moving average of $21.96. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.The business had revenue of $32.12 million for the quarter.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on BBNX shares. Wall Street Zen downgraded shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Robert W. Baird decreased their price target on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Finally, Lake Street Capital set a $20.00 target price on Beta Bionics in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors and hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Beta Bionics in the first quarter valued at approximately $95,000. Goldman Sachs Group Inc. purchased a new position in Beta Bionics during the 1st quarter worth approximately $715,000. Woodline Partners LP purchased a new position in Beta Bionics during the 1st quarter worth approximately $1,530,000. Strs Ohio acquired a new stake in Beta Bionics during the 1st quarter valued at approximately $29,000. Finally, Rhumbline Advisers acquired a new stake in Beta Bionics during the 1st quarter valued at approximately $158,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.